Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
Pushpendra Goswami1, Esther N Oliva2, Tatyana Ionova3
1School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Frontiers in Pharmacology
|October 5, 2020
Summary
The hematological malignancy (HM)-specific patient-reported outcome measure (HM-PRO) demonstrates strong construct validity, confirming its ability to accurately assess health-related quality of life in patients with blood cancers.
Area of Science:
- Oncology
- Psychometrics
- Health Services Research
Background:
- Validity is crucial for outcome measures, ensuring they accurately reflect what they intend to assess.
- The hematological malignancy (HM)-specific patient-reported outcome measure (HM-PRO) is a new instrument for clinical practice and research.
- This study provides evidence for the construct validity of the HM-PRO, focusing on convergent and divergent validity.
Purpose of the Study:
- To provide evidence for the construct validity of the HM-PRO.
- To assess the convergent and divergent validity of the HM-PRO against established hematology instruments.
- To support the reliable use of the HM-PRO in clinical practice and research.
Main Methods:
- A prospective cross-sectional design was employed.
- 905 patients with various hematological malignancies were recruited from UK hospitals and patient organizations.
- Patients completed the HM-PRO, FACT-G, and EORTC QLQ-C30 questionnaires.
Main Results:
- The HM-PRO Part A total score showed high correlations with functional scales of EORTC QLQ-C30 (e.g., Physical -0.71, Role -0.72) and FACT-G (e.g., Physical -0.74, Overall -0.74).
- The HM-PRO Part B total score demonstrated high correlations with symptom scales of EORTC QLQ-C30 (e.g., Fatigue -0.74, Pain -0.59) and individual symptom items (e.g., Dyspnea 0.51).
- All correlations were statistically significant (p < 0.001).
Conclusions:
- The study provides strong evidence for the construct validity of the HM-PRO.
- The HM-PRO accurately measures health-related quality of life issues in hematological malignancy patients.
- This supports the trustworthy interpretation of HM-PRO scores by clinicians in routine practice.
Keywords:
HM-PROclinical practiceclinical researchconstruct validityhematological malignancyquality of lifesymptomsMore Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
557
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
557
01:24Kaplan-Meier Approach
443
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
443
01:22Bone Marrow Sampling and Transplants
685
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
685
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
293
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
293